Home › Merck Receives Complete Response Letter for Suvorexant, Mercks Investigational Medicine for Insomnia
 

Keywords :   


Merck Receives Complete Response Letter for Suvorexant, Mercks Investigational Medicine for Insomnia

2013-07-01 14:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for suvorexant, Mercks investigational medicine for the treatment of insomnia. In the Complete Response Letter, the FDA advised Merck that: Language:  English Contact:  MerckMedia Contacts:Steve Cragle, 415-845-1256orTracy Ogden, 267-305-2301orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: complete response letter medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Cheap TVs ahead of Euros help slow price inflation
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 14A
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Atlantic Tropical Weather Outlook
02.07Eastern North Pacific Tropical Weather Outlook
02.07Murdoch Netflix rival to launch in UK
02.07Hurricane Beryl Forecast Discussion Number 14
More »